Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia.
Gut microbiota
Inflammation
Lung injury
Shen-ling-bai-zhu-san
Streptococcus pneumoniae
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
27 May 2020
27 May 2020
Historique:
received:
12
02
2020
accepted:
19
05
2020
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Shen-ling-bai-zhu-san (SLBZS) regulates inflammation and gut microbiota which are associated with Streptococcus pneumoniae (Spn)-induced pneumonia. So, we studied the therapeutic effect of SLBZS and evaluated whether gut microbiota is associated with the effects of SLBZS in improving Spn-induced pneumonia. Spn-induced pneumonia NIH mice were treated by SLBZS and cefixime. A CT scan was performed and Myeloperoxidase (MPO) activity in lung homogenates was determined using the MPO Colorimetric Assay Kit. Inflammation levels in lung homogenates were measured using ELISA. Bacterial load was coated on a TSAII sheep blood agar. Intestinal gut microbiota information was analyzed according to sequencing libraries. SLBZS decreased bacterial load, reduced wet/dry weight ratio, inhibited myeloperoxidase activity, reduced the neutrophils count, and ameliorated lung injury. Furthermore, SLBZS inhibited interleukin (IL)-1β, IL-6, tumor necrosis factor-α, IL-2, IL-8, IL-12, and interferon-γ secretion and enhanced IL-10 secretion. These results suggest that SLBZS ameliorates lung injury in mice with Spn-induced pneumonia. Moreover, SLBZS reduced inflammatory cytokine levels in a concentration-dependent manner and increased gut microbiota abundance and diversity. After SLBZS treatment, bacteria such as Epsilonbacteraeota, Bacteroidetes, Actinobacteria, Proteobacteria, and Patescibacteria were significantly reduced, while Tenericutes and Firmicutes were significantly increased. SLBZS ameliorates inflammation, lung injury, and gut microbiota in mice with S. pneumoniae-induced pneumonia.
Sections du résumé
BACKGROUND
BACKGROUND
Shen-ling-bai-zhu-san (SLBZS) regulates inflammation and gut microbiota which are associated with Streptococcus pneumoniae (Spn)-induced pneumonia. So, we studied the therapeutic effect of SLBZS and evaluated whether gut microbiota is associated with the effects of SLBZS in improving Spn-induced pneumonia.
METHODS
METHODS
Spn-induced pneumonia NIH mice were treated by SLBZS and cefixime. A CT scan was performed and Myeloperoxidase (MPO) activity in lung homogenates was determined using the MPO Colorimetric Assay Kit. Inflammation levels in lung homogenates were measured using ELISA. Bacterial load was coated on a TSAII sheep blood agar. Intestinal gut microbiota information was analyzed according to sequencing libraries.
RESULTS
RESULTS
SLBZS decreased bacterial load, reduced wet/dry weight ratio, inhibited myeloperoxidase activity, reduced the neutrophils count, and ameliorated lung injury. Furthermore, SLBZS inhibited interleukin (IL)-1β, IL-6, tumor necrosis factor-α, IL-2, IL-8, IL-12, and interferon-γ secretion and enhanced IL-10 secretion. These results suggest that SLBZS ameliorates lung injury in mice with Spn-induced pneumonia. Moreover, SLBZS reduced inflammatory cytokine levels in a concentration-dependent manner and increased gut microbiota abundance and diversity. After SLBZS treatment, bacteria such as Epsilonbacteraeota, Bacteroidetes, Actinobacteria, Proteobacteria, and Patescibacteria were significantly reduced, while Tenericutes and Firmicutes were significantly increased.
CONCLUSION
CONCLUSIONS
SLBZS ameliorates inflammation, lung injury, and gut microbiota in mice with S. pneumoniae-induced pneumonia.
Identifiants
pubmed: 32460745
doi: 10.1186/s12906-020-02958-9
pii: 10.1186/s12906-020-02958-9
pmc: PMC7254717
doi:
Substances chimiques
Drugs, Chinese Herbal
0
shen ling bai zhu
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
159Subventions
Organisme : Major Medical and Health projects of Zhongshan Science and Technology Plan
ID : 2016B1004
Références
Thorax. 2020 Jan;75(1):38-49
pubmed: 31594801
PLoS One. 2019 Aug 15;14(8):e0221199
pubmed: 31415655
FEMS Immunol Med Microbiol. 2012 Apr;64(3):295-313
pubmed: 22268692
J Thorac Dis. 2016 Jun;8(6):1316-22
pubmed: 27293852
Evid Based Complement Alternat Med. 2014;2014:671013
pubmed: 24795769
Clin Med Insights Circ Respir Pulm Med. 2019 Jul 31;13:1179548419862790
pubmed: 31391784
Emerg Microbes Infect. 2018 May 23;7(1):92
pubmed: 29789582
Expert Opin Pharmacother. 2017 Aug;18(11):1039-1048
pubmed: 28598693
Ann Ib Postgrad Med. 2015 Dec;13(2):72-8
pubmed: 27162517
Environ Health Prev Med. 2020 Jan 7;25(1):2
pubmed: 31910807
Microbiol Res. 2017 Jul;200:14-24
pubmed: 28527760
Front Microbiol. 2017 Aug 23;8:1613
pubmed: 28878760
Inflammation. 2019 Oct;42(5):1741-1753
pubmed: 31267272
PLoS One. 2013 Oct 07;8(10):e74957
pubmed: 24116019
Arch Pharm Res. 2017 Aug;40(8):885-893
pubmed: 28735461
Zhongguo Zhong Yao Za Zhi. 2018 Dec;43(24):4759-4764
pubmed: 30717515
Zhongguo Dang Dai Er Ke Za Zhi. 2016 Feb;18(2):113-6
pubmed: 26903056
Infect Immun. 2015 Oct;83(10):4003-14
pubmed: 26216419
Nat Rev Gastroenterol Hepatol. 2017 May;14(5):263-264
pubmed: 28325929
Toxins (Basel). 2017 Oct 12;9(10):
pubmed: 29023377
Oxid Med Cell Longev. 2019 Jun 23;2019:8194804
pubmed: 31341536
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1126-1133
pubmed: 31260638
Crit Care Med. 2019 Sep;47(9):e735-e743
pubmed: 31162191
Afr J Tradit Complement Altern Med. 2013 Nov 02;11(1):213-21
pubmed: 24653580
Evid Based Complement Alternat Med. 2017;2017:4293291
pubmed: 28808474
Genome Biol. 2013 Jan 14;14(1):R1
pubmed: 23316946
Medicine (Baltimore). 2018 Sep;97(38):e12337
pubmed: 30235688
Microbiol Spectr. 2019 Mar;7(2):
pubmed: 30873934
PLoS One. 2018 Jul 18;13(7):e0200504
pubmed: 30020995
Comp Med. 2007 Feb;57(1):82-9
pubmed: 17348295
Int J Biol Macromol. 2017 Dec;105(Pt 3):1622-1629
pubmed: 28219687
Immunology. 2015 Sep;146(1):100-12
pubmed: 26032199
Trials. 2018 Nov 12;19(1):620
pubmed: 30419961
Nutr Clin Pract. 2019 Feb;34(1):156-162
pubmed: 30088841
Am J Transplant. 2016 Jun;16(6):1766-78
pubmed: 26693965
Stem Cell Res Ther. 2018 Apr 12;9(1):101
pubmed: 29650044
Trials. 2019 Dec 30;20(1):817
pubmed: 31888702
Biomed Pharmacother. 2018 Jun;102:1025-1036
pubmed: 29710519
J Ethnopharmacol. 2019 Mar 1;231:355-362
pubmed: 30071269
Eur J Clin Microbiol Infect Dis. 2013 May;32(5):637-45
pubmed: 23291779
Gut. 2016 Apr;65(4):575-83
pubmed: 26511795
Front Cell Infect Microbiol. 2018 Apr 18;8:118
pubmed: 29755958